Results 121 to 130 of about 2,707 (157)

Expanding Tuberculosis Drug Resistance Prediction beyond binary: Deep Learning for Minimum Inhibitory Concentration prediction

Wang L, Campino S, Clark TG, Phelan JE.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Delamanid: First Global Approval

Drugs, 2014
Delamanid, a nitro-dihydro-imidazooxazole derivative, has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy.
Nicola J, Ryan, Jin Han, Lo
openaire   +2 more sources

Bedaquiline and delamanid in tuberculosis

Expert Opinion on Pharmacotherapy, 2015
In recent years, a pressing need to develop new, effective and safe drugs against tuberculosis (TB) has continued. Poor adherence to a long therapeutic regimen against TB, intermittent drug use, errors in medical prescriptions, low quality of old TB drugs and ineffective TB control have led to the emergence of resistant TB.Two new drugs have gained ...
S. Esposito, S. Bianchini, F. Blasi
openaire   +3 more sources

Delamanid for Extensively Drug-Resistant Tuberculosis

New England Journal of Medicine, 2015
Therapeutic options for extensively drug-resistant tuberculosis infection are limited. In this post-hoc analysis, a new drug, delamanid, shows some activity in the treatment of XDR-TB.
Rajesh, Gupta, Lawrence J, Geiter, Charles D, Wells, Mengqui, Gao, Andra, Cirule, Heping, Xiao   +5 more
openaire   +2 more sources

Delamanid in the treatment of multidrug-resistant tuberculosis

The International Journal of Tuberculosis and Lung Disease, 2016
Otsuka has been engaged in anti-tuberculosis drug development efforts for over 30 years, and is the leading private sector funder of tuberculosis (TB) research and development. Delamanid (DLM), discovered by Otsuka's scientists, has been shown to provide benefit with respect to short-term surrogate markers and long-term treatment outcomes, and it has ...
R, Gupta, C D, Wells, N, Hittel, J, Hafkin, L J, Geiter   +4 more
openaire   +2 more sources

Delamanid for the treatment of pulmonary multidrug resistant tuberculosis

Drugs of Today, 2015
Out of a handful of new drugs currently in clinical trials for the treatment of tuberculosis, delamanid, a nitro-dihydro-imidazole derivative, has successfully emerged. Delamanid is a novel mycolic acid biosynthesis inhibitor that is equally potent against drug-sensitive as well as drug-resistant Mycobacterium tuberculosis.
R, Thakare, I, Soni, A, Dasgupta, S, Chopra   +3 more
openaire   +2 more sources

Delamanid

Reactions Weekly, 2019
  +4 more sources

Delamanid

Reactions Weekly, 2023
openaire   +1 more source